Cervical screening
≈ 4 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Cervical cancer screening is a medical screening test designed to identify risk of cervical cancer. Cervical screening may involve looking for viral DNA, and/or identifying abnormal, potentially precancerous cells within the cervix as well as cells that have progressed to early stages of cervical cancer. One goal of cervical screening is to allow for intervention and treatment so abnormal lesions can be removed before progression to cancer.
An additional goal is to decrease mortality from cervical cancer by identifying cancerous lesions in their early stages and providing treatment before progression to more invasive disease. Currently available screening tests fall into three categories: molecular, cytologic, and visual inspection. Molecular screening tests include nucleic acid amplification tests (NAAT), which identify high-risk human papillomavirus (HPV) strains. Cytologic tests include conventional Pap smear and liquid-based cytology.
Visual Inspection tests involve application of a solution to enhance identification of abnormal areas and can utilize the naked eye or a colposcope/magnifying camera. Medical organizations of different countries have unique guidelines and screening recommendations.…
Cervical cancer screening is a medical screening test designed to identify risk of cervical cancer. Cervical screening may involve looking for viral DNA, and/or identifying abnormal, potentially precancerous cells within the cervix as well as cells that have progressed to early stages of cervical cancer. One goal of cervical screening is to allow for intervention and treatment so abnormal lesions can be removed before progression to cancer.
An additional goal is to decrease mortality from cervical cancer by identifying cancerous lesions in their early stages and providing treatment before progression to more invasive disease. Currently available screening tests fall into three categories: molecular, cytologic, and visual inspection. Molecular screening tests include nucleic acid amplification tests (NAAT), which identify high-risk human papillomavirus (HPV) strains. Cytologic tests include conventional Pap smear and liquid-based cytology.
Visual Inspection tests involve application of a solution to enhance identification of abnormal areas and can utilize the naked eye or a colposcope/magnifying camera. Medical organizations of different countries have unique guidelines and screening recommendations. The World Health Organization has also published guidelines to increase screening and improve outcomes for all women, taking into consideration differences in resource availability of regions.
Management of abnormal screening results can include surveillance, biopsy, or removal of the suspicious region via surgical intervention. Diagnosis of more advanced cancer stages may require other treatment options such as chemotherapy or radiation.
Nigeria
In Nigeria, cervical cancer is the most common life-threatening disease affecting the female genital tract, with an estimated 10,000 new cases and 8,000 deaths reported within the same period. In sub-Saharan Africa, the HPV 16 strain in present in about 50–70% of cases and the HPV 18 strain in 7–20% of cases. In Nigeria, the conventional Pap smear intervention is currently being used to screen for cervical cancer. In developing countries like Nigeria, the adoption of cervical cancer screening by women is largely affected by a lack of awareness and knowledge of cervical cancer, a lack of a comprehensive policy for cervical cancer prevention, and inadequate publicity of available strategies . It is essential to address the factors limiting cervical cancer screening in Nigeria through policies and health education
Text derived from https://en.wikipedia.org/w/index.php?oldid=1378941680 under CC BY-SA 4.0; modifications have been made.